A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Aug 12, 2021

Keywords

ClinConnect Summary

This clinical trial is studying whether using a lower dose of radiation can effectively treat metastatic tumors that have a specific genetic change called an ATM mutation. The goal is to find the smallest amount of radiation that still works to help manage these tumors, which can spread to other parts of the body. Researchers are looking for participants aged 18 and older who have been diagnosed with cancer that has spread and who have this genetic mutation. To take part, patients should have a good level of health and must be able to give their consent to join the study.

If you or a loved one qualifies for this trial, you can expect to receive targeted radiation treatment while being closely monitored by medical professionals. Participants will need to follow certain guidelines, such as using effective birth control during treatment if they are capable of becoming pregnant. It's important to note that this trial is currently recruiting participants, and it aims to explore a potentially less harmful way to treat metastatic cancer while still being effective.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically confirmed malignancy with at least one metastatic lesion referred for palliative radiotherapy
• • Pathogenic mutation in ATM (somatic and germline allowed)
• • ECOG performance status 0-2
• • Age ≥ 18 years.
• • Able to provide informed consent.
• • Patients at reproductive potential must agree to practice an effective contraceptive method during radiation treatments.
• • Expected life expectancy of at least 6 months
• Exclusion Criteria:
• • Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances.
• • Serious medical co-morbidities precluding radiotherapy.
• • Pregnant or breast-feeding women.
• • Lesions excluded from de-escalation include regions in which the risk of local disease progression is unacceptably high, including CNS disease and cord compression, and areas in which re-irradiation would not be feasible, including spinal cord overlap.